Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT

Nivedita Sain, Bhavani Krishnan, Michael G. Ormerod, Assunta De Rienzo, Wai M. Liu, Stanley B. Kaye, Paul Workman, Ann L. Jackman

Open source

DOI
10.1158/1535-7163.mct-05-0445
Published
2006-05-01
Container
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Open access
unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1158/1535-7163.mct-05-0445,
  title = {Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT},
  author = {Nivedita Sain and Bhavani Krishnan and Michael G. Ormerod and Assunta De Rienzo and Wai M. Liu and Stanley B. Kaye and Paul Workman and Ann L. Jackman},
  year = {2006},
  journal = {Molecular Cancer Therapeutics},
  doi = {10.1158/1535-7163.mct-05-0445},
  url = {https://doi.org/10.1158/1535-7163.mct-05-0445}
}

RIS

TY  - JOUR
TI  - Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
AU  - Nivedita Sain
AU  - Bhavani Krishnan
AU  - Michael G. Ormerod
AU  - Assunta De Rienzo
AU  - Wai M. Liu
AU  - Stanley B. Kaye
AU  - Paul Workman
AU  - Ann L. Jackman
PY  - 2006
JO  - Molecular Cancer Therapeutics
DO  - 10.1158/1535-7163.mct-05-0445
UR  - https://doi.org/10.1158/1535-7163.mct-05-0445
ER  - 

APA

Sain, N., Krishnan, B., Ormerod, M. G., Rienzo, A. D., Liu, W. M., Kaye, S. B., Workman, P., & Jackman, A. L. (2006). Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0445

Source records